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Abstract
Background: Fusion of placental villous cytotrophoblasts with the overlying syncytiotrophoblast is essential for the
maintenance of successful pregnancy, and disturbances in this process have been implicated in pathological conditions
such as pre-eclampsia and intra-uterine growth retardation. Caveolin-1 has been shown to be expressed in human villous
cytotrophoblast and to be downregulated during fusion into syncytiotrophoblast but it is unclear whether it plays a role in
this process.
Methodology/Principal Findings: We used RNA interference to determine whether caveolin-1 plays a role in differentiation
and fusion in the BeWo choriocarcinoma cell line, a model of villous cytotrophoblast fusion. Assessment of cell fusion by
desmosomal protein immunostaining revealed that cells transfected with caveolin-1 siRNA showed significantly enhanced
fusion in response to treatment with dibutyryl cyclic AMP compared with cells transfected with a non-silencing control.
Furthermore, caveolin-1 knockdown alone was sufficient to promote spontaneous fusion. In addition, biochemical
differentiation, assessed by expression of placental alkaline phosphatase, was upregulated in caveolin-1 siRNA-transfected
cells, with or without dbcAMP treatment. Assessment of Akt phosphorylation showed that caveolin-1 knockdown resulted
in a significant reduction in phosphorylation at Thr
308.
Conclusions/Significance: Taken together, these results suggest that caveolin-1 regulates BeWo cell differentiation and
fusion, possibly through a mechanism involving modulation of Akt activity.
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Introduction
Fusion of proliferating villous cytotrophoblast stem cells is
essential to form, grow and maintain the syncytiotrophoblast
epithelium of the human placenta [1]. Syncytiotrophoblast is in
direct contact with maternal blood and serves key placental
functions such as nutrient and gas exchange, and the synthesis of
steroid and peptide hormones [2]. Disturbances in this process
may be involved in pathological conditions such as pre-eclampsia
and intra-uterine growth retardation [3,4]. In studies of primate
trophoblasts, it was discovered that syncytiotrophoblast formation
originates as a result of fusion of mononuclear cytotrophoblasts
[1]. Expansion of the syncytiotrophoblast throughout gestation
then occurs as cytotrophoblasts proliferate, differentiate and finally
fuse with the overlying syncytiotrophoblast. Therefore, trophoblast
fusion is crucial for the beginning and maintenance of successful
pregnancy. Indeed, it has been suggested that disturbances in this
process may be involved in pathological conditions such as pre-
eclampsia and intra-uterine growth retardation [3,4]; however, the
mechanism by which it occurs remains poorly understood. It has
been shown that isolated cytotrophoblasts aggregate and fuse in
vitro to form multinucleated syncytiotrophoblast [5] and this is
enhanced by EGF or agents which increase intracellular cAMP
levels. A number of proteins have been implicated in the fusion
process, including envelope proteins derived from human
endogenous retroviruses (HERVs) [6], caspase-8 [7], connexin
43 [8] and ADAM proteins [9].
Caveolin is the major structural component of caveolae,
plasmalemmal organelles which function as macromolecular
vesicular transporters and organizers of multiple signalling
molecules [10]. Three caveolin isoforms are expressed in
mammalian cells; caveolin-1 and caveolin-2 are co-expressed in
most cell types whereas caveolin-3 is specifically expressed in
muscle cells [11]. Although it was initially identified as a
component of caveolae [11], caveolin-1 expression is not restricted
to these organelles; it has been shown to localize to other cellular
compartments including secretory vesicles, cytoplasm and mito-
chondria [12]. In its role as a scaffolding protein, caveolin-1 is
capable of recruiting numerous signalling molecules as well as
regulating their activity [13,14]. Whilst many proteins, such as
EGF receptor [15] and protein kinase C [16] are negatively
regulated by direct interaction with caveolin-1 through its
scaffolding domain, there are some instances where association
with caveolin-1 is essential for activation, such as in adipocytes
where interaction of the insulin receptor with caveolin-1 is
required for successful insulin signaling [17].
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studies have revealed that cytotrophoblast differentiation and
fusion appears to be associated with a marked depletion in
detectable caveolin-1 levels [18]. However, it is not known
whether this depletion is a cause or consequence of syncytial
fusion. A possible role for caveolin in cell fusion has been
demonstrated by the finding that manipulation of the levels of
caveolin-3 in myoblasts affects the ability of these cells to fuse into
multinucleated myotubes [19]. Therefore, in this study we have
used RNA interference to knock down expression of caveolin-1
and assess its role in syncytial fusion in the BeWo choriocarcinoma
cell line, a widely-used model of trophoblast fusion which expresses
similar levels of caveolin-1 to those in native cytotrophoblasts [20].
Materials and Methods
Cell culture
BeWo cells obtained from the European Collection of Cell
Cultures (Porton Down, UK) were cultured in full growth medium
(Dulbecco’s modified Eagle’s medium/Ham’s F12 supplemented
with 2 mM l-glutamine, 100 IU/ml penicillin, 100 mg/ml strep-
tomycin, 0.25 mg/ml amphotericin (Sigma) and 10% (v/v) fetal
calf serum (Serum Laboratories International)). Cells were grown
as a monolayer at a density of 10
7 cells per 75 mm
2 flask at 37uC
in 95% air and 5% CO2, with medium changed every 48 h. For
passages, cells were detached with trypsin/EDTA (Life Technol-
ogies) at 37uC, then washed in complete culture medium and
replated.
siRNA transfection
Cells were plated at 5610
4 cells/ml into 24-well plates and
transfected immediately with caveolin-1 siRNA (sense 59-
GCCGUGUCUAUUCCAUCUA-39; antisense 59-UAGAUG-
GAAUAGACACGGC-39) or a non-silencing negative control
siRNA (sense 59-UUCUCCGAACGUGUCACGU-39; antisense
59-ACGUGACACGUUCGGAGAA-39) (Qiagen) using Hiperfect
transfection reagent (Qiagen) following protocols provided by the
manufacturer. After 48 h of incubation the cells were either
harvested for protein extraction and immunoblotting or treated as
described below for immunocytochemistry and analysis of cell
fusion.
Immunoblotting
Cells were washed with PBS and lysed directly into SDS–PAGE
loading buffer. Protein concentration was determined using a BCA
protein assay kit (Pierce). Proteins (5 mg) were resolved by SDS–
PAGE and transferred to PVDF membrane. Membranes were
then incubated in blocking buffer (Tris-buffered saline with 5%
BLOTTO (Santa Cruz) and 0.1% Tween) for 45 minutes at room
temperature then incubated with the appropriate primary
antibodies in blocking buffer overnight at 4uC. Reactions were
visualized by using a suitable secondary antibody conjugated to
horseradish peroxidase (Dako) in blocking buffer at room
temperature for 2 hours and an enhanced chemiluminescence
system (Pierce). Primary antibodies used were: anti-caveolin-1
(#sc-894, Santa Cruz), anti-b-actin (#ab6276, Abcam), anti-
phospho-Akt Thr
308 (#2965), anti-phospho-Akt Ser
473 (#4060),
anti-Akt (#4691) (all New England Biolabs) and anti-placental
alkaline phosphatase (NDOG2, Tannetta et al., 2008).
Immunocytochemistry
Cells for desmosomal protein staining were fixed with ice-cold
methanol and stored at 4uC in PBS until processing. For placental
alkaline phosphatase staining, cells were fixed in 4% PFA in PBS,
otherwise cells were permeabilised by incubation in PBS
containing 0.5% Triton-X 100 (Sigma) for 10 min at room
temperature. All cells were blocked for 1 h at room temperature
with PBS containing 10% normal human serum and 0.1% Tween-
20, then incubated overnight at 4uC with primary antibodies (anti-
desmosomal protein (#D1286, Sigma), anti-placental alkaline
phosphatase, see above) diluted in blocking buffer before washing
(265 min) in PBS. Negative controls comprised mouse IgG alone.
Cells were next stained with Alexa Fluor 488 conjugated
secondary antibody (Invitrogen) in blocking buffer, the nuclei
stained with Hoechst 33342 (1 mg/ml in PBS; Invitrogen) and
washed (265 min) and stored in PBS. They were examined using
a Leica DMIRE2 inverted fluorescence microscope and photo-
graphed using a Hamamatsu Orca monochrome camera and
Simple PCI software (C Imaging).
Cell fusion analysis
Cells were induced to fuse by replacing full growth medium with
Dulbecco’s modified Eagle’s medium containing 2.5% (v/v) fetal
calf serum and 1 mM dibutyryl cyclic AMP, as described
previously [20]. At the indicated time points the cells were washed
with PBS and fixed in methanol at 220uC for 10 minutes.
Intercellular boundaries were then visualized by immunocyto-
chemical staining with an antibody to desmosomal protein as
described above. Ten random fields containing approximately 300
nuclei each were photographed for subsequent analysis. Compos-
ites of Hoechst 33342 stained nuclei and Alexa Fluor 488 stained
desmosomal protein were made, then all nuclei were counted and
the percentage of nuclei contained within multinucleated ($2
nuclei) syncytia was calculated, as described previously [21].
Statistical analysis
The data presented represent mean 6 SEM of at least three
separate experiments. Differences between control and caveolin-1
siRNA transfected cells were analysed by ANOVA and a P-value
of less than 0.05 was considered to be statistically significant.
Results
siRNA-mediated downregulation of caveolin-1
expression in BeWo cells
BeWo cells were transfected with siRNA duplexes targeted to
human caveolin-1 mRNA (Cav-1 siRNA) or a non-silencing
control which has no homology to any known mammalian gene.
Caveolin-1 expression was efficiently downregulated in a dose-
dependent manner by transfection (48 h) with Cav-1 siRNA, as
demonstrated by an immunoblot of BeWo cell lysates (Fig. 1A).
Transfection with the non-silencing control did not affect caveolin-
1 expression compared with mock-transfected controls. Levels of
b-actin were unaffected by transfection with either Cav-1 or non-
silencing siRNA. Densitometric analysis revealed that transfection
with 50 nM Cav-1 siRNA resulted in a 72% knockdown of
caveolin-1 expression compared with the non-silencing control
(Fig. 1B). For all further experiments, cells were transfected with
siRNA duplexes at 50 nM.
Caveolin-1 knockdown enhances BeWo cell fusion
The effect of caveolin-1 knockdown on BeWo cell fusion was
assessed by transfecting cells with Cav-1 or control siRNA for 48 h
then treating with low-serum medium in the presence or absence
of 1 mM dbcAMP, a cell-permeable analogue of cyclic AMP.
Treatment with dbcAMP resulted in a decrease in Cav-1
expression and the silencing effect of Cav-1 siRNA was
maintained over the 48 h treatment period, i.e. 96 h in total after
Caveolin and BeWo Fusion
PLoS ONE | www.plosone.org 2 May 2010 | Volume 5 | Issue 5 | e10529the commencement of transfection (Figure 2A). To assess fusion,
intercellular boundaries were visualised by staining with an
antibody to desmosomal protein [22]. Figure 2B shows that after
24 h of treatment there was little evidence of cell fusion in control
transfected cultures, as shown by the presence of intercellular
boundaries, whereas in cells transfected with Cav-1 siRNA there
were clear areas of multinucleated syncytia where the intercellular
boundaries had been lost. Cell fusion was quantified by calculating
the percentage of nuclei contained within multinucleated syncytia
[21]. Without dbcAMP, Cav-1 siRNA-transfected cells showed a
significant increase in the percentage of nuclei contained in
syncytia compared with untreated cells transfected with non-
silencing control (12.1% vs 4.4%, and 12.1% vs 6.1%, at 24 h and
48 h respectively; Fig. 2C). Similarly, with dbcAMP, the number
of nuclei in syncytia was significantly increased in Cav-1 siRNA-
transfected cells after 24 h treatment compared with controls
(26.0% vs 5.4%). There was also an increase at 48 h (21.3% vs
14.1%) but this was not statistically significant.
Placental alkaline phosphatase expression is upregulated
by caveolin-1 knockdown
Differentiation and fusion of cytotrophoblasts into syncytia is
accompanied by a strong upregulation of placental alkaline
phosphatase (PLAP) expression [23]. Therefore we assessed the
effect of caveolin-1 knockdown on PLAP expression in BeWo cells.
Immunoblotting showed that in proliferating, undifferentiated
BeWo cells PLAP levels were extremely low but were increased by
24 h following treatment with low-serum medium containing
dbcAMP, and by 48 h after treatment with low-serum medium
alone (Fig. 3A). In cav-1 siRNA transfected cells PLAP expression
upon dbcAMP treatment was significantly enhanced at both 24 h
and 48 h compared with control cells (Figs. 3A & 3B).
Furthermore, following treatment with low-serum medium alone,
PLAP expression was significantly higher at 24 h in caveolin-1
siRNA transfected cells. These results were confirmed by
immunocytochemical studies, which revealed an increase in PLAP
expression at 24 h in caveolin-1 siRNA transfected cells compared
with control cells, following treatment in low-serum medium with
or without dbcAMP (Fig. 3C).
Akt phosphorylation is inhibited by caveolin-1
knockdown
Akt has been shown to play a role in myoblast fusion [24] and,
in other cell types, is regulated by caveolin-1 [25,26,27]. Akt is
fully activated after phosphorylation at Thr
308 and Ser
473 by
PDK1 (phosphoinositide-dependent protein kinase 1) or
mTORC2 (mammalian target of rapamycin complex 2) [28].
Therefore, to explore the possibility that caveolin may regulate Akt
activity in trophoblasts we used phosphorylation site-specific
antibodies to study the activation status of Akt in BeWo cells
transfected with control or Cav-1 siRNA. Immunoblots revealed
that in control transfected cells Akt was phosphorylated at both
Thr
308 and Ser
473 (Fig. 4A). In cells transfected with Cav-1 siRNA
there was a reduction in Thr
308 phosphorylation (Fig. 4A) relative
to control cells. Total Akt levels were unaffected by caveolin-1
knockdown. Densitometric analysis showed that Thr
308 phosphor-
ylation was significantly reduced by 38% in Cav-1 siRNA
transfected cells (Fig. 4B). No significant difference in Ser
473
phosphorylation was observed in Cav-1 siRNA transfected cells
compared to controls (Figs 4A & B).
Discussion
In this study we show for the first time that downregulation of
caveolin-1 enhances differentiation and fusion in the BeWo
human choriocarcinoma cell line, as assessed using both
morphological and biochemical criteria. These results suggest that
caveolin-1 may play an important role in the regulation of these
processes in normal and/or pathological pregnancies.
We have used BeWo cells as a model of trophoblast
differentiation and fusion. This is a well characterised model
which shares important properties with freshly isolated human
villous cytotrophoblasts, most significantly the ability to fuse and
form large multinucleated syncytia [29]. Mechanistic aspects of
intercellular fusion, such as externalisation of phosphatidylserine
[30] and upregulation of syncytin-1 expression [31,32] have been
shown to be common to both cell types. Importantly, in the
context of this study, BeWo cells and primary villous cytotropho-
blasts express similar levels of caveolin-1 [20] suggesting that the
results obtained from knockdown of the protein in BeWo cells as
described here will be pertinent to understanding its role in
trophoblast fusion in placental development.
Cell fusion to form syncytia is a rare event in cell biology and is
restricted to striated muscle fibres, chondro- or osteoclasts,
macrophage giant cells and syncytiotrophoblast [3,33]. Whilst no
data prior to this study exist on a role for caveolin in trophoblast
fusion, it has been demonstrated that the ability of myoblasts to
fuse to form multinucleated myotubes is affected by their level of
Figure 1. siRNA-mediated downregulation of caveolin-1 ex-
pression in BeWo cells. A, BeWo cells were transfected with the
indicated concentrations of caveolin-1(Cav-1) siRNA or a non-silencing
control siRNA. After 48 h cells were lysed and levels of caveolin-1 and b-
actin were assessed by immunoblotting. B, densitometric analysis of
immunoblots assessed for caveolin-1 expression and normalised to b-
actin expression, in cells transfected for 48 h with 50 nM Cav-1 siRNA or
non-silencing control siRNA. Results are presented as mean 6 SEM for
three separate experiments, *p,0.001 compared with control trans-
fected cells (determined by ANOVA).
doi:10.1371/journal.pone.0010529.g001
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enhances or inhibits fusion. In mice it has been shown that
overexpression of caveolin-3 inhibits myoblast fusion whereas the
process is enhanced by a lack of caveolin-3 [19]. However, more
recent studies in zebrafish have suggested that caveolin-3
deficiency may lead to a reduction in myoblast fusion [34]. In
the human placenta, caveolin-1 is strongly expressed in endothelial
cells, with lower levels in cytotrophoblasts and mesenchymal cells,
and barely detectable expression in syncytiotrophoblast
[35,36,37]. This reduction in expression of caveolin-1 in
syncytiotrophoblast compared to cytotrophoblast, together with
the observation that differentiation and fusion of cytotrophoblast
in vitro is accompanied by its depletion [18], led us to hypothesise
that it may play an important role in these processes. In the
present study, downregulation of caveolin-1 by RNA interference
resulted in an augmentation of dbcAMP-induced cell fusion, and
also induced fusion in the absence of dbcAMP. We found that, in
control cells, dbcAMP had no effect at 24 h but induced fusion at
48 h. At both timepoints fusion was enhanced in caveolin-1
siRNA-transfected cells compared with control cells following
dbcAMP treatment. Furthermore, in the absence of dbcAMP,
caveolin-1 siRNA transfection resulted in a marked and significant
increase in syncytium formation at both 24 h and 48 h,
demonstrating that caveolin-1 downregulation alone is sufficient
to promote trophoblast fusion. Interestingly, no further increase in
the fusion rate in caveolin-1 siRNA-transfected cells from 24 h to
48 h was observed. This was not due to a lessening of the silencing
effect over time, since it was clear that caveolin-1 expression was
maintained at lower levels in caveolin-1 siRNA-transfected cells
even after 48 h of treatment with dbcAMP, i.e. 96 h after the
commencement of transfection. The reason for this effect is
therefore unclear but it is possible that the lack of increase in
observed fusion from 24 h to 48 h may be explained by death
and/or sloughing off of some fused cells from the tissue culture
Figure 2. Assessment of cell fusion. A, BeWo cells were transfected with Cav-1 siRNA or non-silencing control siRNA. After 48 h the cells were
treated with low (2.5%) serum medium containing 1 mM dbcAMP. At the indicated timepoints, cells were lysed and levels of caveolin-1 and b-actin
were determined by immunoblotting. B, Cells were transfected as in A then treated with low (2.5%) serum medium in the absence of dbcAMP
(1 mM), as indicated, for 24 h. Cells were fixed, immunostained for desmosomal protein (green) and counterstained with Hoechst (blue). C, cells were
treated as in B and cell fusion was quantified at 24 h (left panel) and 48 h (right panel) as described in Materials Methods& . Results are presented as
mean 6 SEM for three separate experiments, *p,0.001, **p,0.05 compared with control transfected cells (determined by ANOVA). Scale
bar=100 mm.
doi:10.1371/journal.pone.0010529.g002
Caveolin and BeWo Fusion
PLoS ONE | www.plosone.org 4 May 2010 | Volume 5 | Issue 5 | e10529plate at the later time point. Higher rates of fusion were observed
after a combination of caveolin-1 knockdown and dbcAMP
treatment than with either condition alone, suggesting that both
conditions might be acting to enhance a common signalling
pathway; it is also possible, however, that caveolin-1 downregu-
lation may act to stimulate fusion by a mechanism which is distinct
from that elicited by cyclic AMP. In addition to its effect on fusion
we also looked at the impact of caveolin-1 knockdown on
biochemical differentiation of BeWo cells. Although PLAP cannot
be regarded as a bona fide marker of syncytiotrophoblast, since it
is expressed at low levels in some cytotrophoblasts, it is clearly
upregulated during trophoblast differentiation and fusion [23]. We
found that caveolin-1 knockdown enhanced PLAP expression in
dbcAMP-treated cells, whilst in the absence of dbcAMP, caveolin-
1 downregulation resulted in a more rapid expression of PLAP
compared with non-silencing controls. These results show that
cav-1 knockdown enhances biochemical differentiation of BeWo
cells, mirroring its effects on morphological differentiation
described in the fusion experiments.
The mechanism by which caveolin-1 regulates BeWo cell
fusion remains to be elucidated. In myoblasts, Akt activity has
been shown to be required for differentiation into myotubes and
their subsequent survival and growth [24]. Since Akt is expressed
by trophoblast [38] and, in other cell types, can be either
positively or negatively regulated by caveolin-1 [25,26,27], we
decided to investigate the effect of caveolin-1 knockdown on Akt
activation in trophoblast using phosphorylation site-specific
antibodies. Full activation of Akt requires phosphorylation at
both Thr
308 and Ser
473 [28]. We found that Akt was
constitutively phosphorylated in BeWos at Thr
308 and Ser
473
and that downregulation of caveolin-1 resulted in a significant
reduction of phosphorylation at Thr
308. A reduction in Ser473
phosphorylation in caveolin-1 knockdown cells was also observed
but this was not found to be statistically significant. Interestingly,
it has been demonstrated that in differentiating myoblasts Akt
Thr
308 phosphorylation is downregulated [24], and that dephos-
phorylation at this site leads to an alteration in the activity of a
specific subset of Akt target proteins [39]. One such protein is the
FoxO1 forkhead transcription factor family member, which has
been shown to regulate myoblast fusion [40]. Furthermore,
dephosphorylation of Akt is catalysed by protein phosphatases
PP1 and PP2A [41,42,43] and, intriguingly, it has been shown
that caveolin-1 can interact with both these phosphatases and
negatively regulate their activity [25]. It is tempting, therefore, to
speculate that the effects of caveolin on BeWo cell fusion may be
mediated through its regulation of phosphorylation of Akt and
Figure 3. Assessment of placental alkaline phosphatase expression. A, BeWo cells were transfected with Cav-1 siRNA or non-silencing
control siRNA. After 48 h the cells were treated with low (2.5%) serum medium in the presence or absence of dbcAMP (1 mM). At the indicated
timepoints (0 h being equivalent to 48 h treatment with siRNA) cells were lysed and levels of PLAP and b-actin were determined by immunoblotting.
B, densitometric analysis of immunoblots showing the level of PLAP, normalised to b-actin levels, in Cav-1 and control transfected cells. C, cells were
treated as in A. After 24 h the cells were fixed, immunostained for PLAP (green) and counterstained with Hoechst (blue). Results are expressed as
mean 6 SEM for three separate experiments, *p,0.05 compared with control transfected cells (determined by ANOVA). Scale bar=100 mm.
doi:10.1371/journal.pone.0010529.g003
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future work.
In conclusion, we show for the first time that the regulation of
caveolin-1 expression could represent an important step in BeWo
cell differentiation and fusion. Experiments in isolated primary
human cytotrophoblasts will allow us to further elucidate the role
of this protein in human trophoblast function.
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